Pioglitazone administration acutely inhibits insulin secretion and increases insulin clearance in Wistar rats. Pioglitazone administration acutely inhibits.

Slides:

Advertisements

Similar presentations

Part 8. Rationale for SGLT2 Inhibitors Inhibit glucose reabsorption in the renal proximal tubule Resultant glucosuria leads to a decline in plasma glucose.

Advertisements

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Fig. 1. Fetal GSIS. Fetal plasma glucose (A) and insulin (B) concentrations determined for the in vivo GSIS study are presented as the mean ± sem for control.

Possible new treatments for Congenital Hyperinsulinism

Volume 24, Issue 2, Pages (June 2017)

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

Volume 130, Issue 1, Pages (January 2006)

by Nicholas J. Laping, Michael P. DeMartino, Joshua E

Chronic effect of 28-day oral administration of vehicle (n = 6–10/group) or aprocitentan 1, 10, and 100 mg/kg per day (n = 6–9/group) on mean arterial.

Hyperinsulinemic-euglycemic clamps revealed that obese TPL2KO mice have an improved insulin sensitivity compared with obese WT mice. Hyperinsulinemic-euglycemic.

Cyp8b1−/− mice have improved islet insulin secretion and increased islet insulin content but unchanged β-cell mass. Cyp8b1−/− mice have improved islet.

VAN GLP-1R kd disturbed postmeal glycemia and insulinemia but did not impair tolerance of an oral glucose bolus. VAN GLP-1R kd disturbed postmeal glycemia.

A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25.

(A) Plasma renin activity in Wistar rats, SHRs, and DOCA-salt rats, n = 8 to 9/group; data are presented as mean ± S.E.M. Dose-response relationship on.

NOx ASR (in mmol/day), arginine Ra (in µmol/kg × min), the fraction of arginine flux converted to NOx (%), and the insulin-mediated glucose disposal (M)

Effect of insulin on hepcidin expression in HepG2 cells.

Comparison of the protective effects of R and S isomers of LA on insulin-stimulated 2-DG uptake. Comparison of the protective effects of R and S isomers.

Body weight, blood glucose, and iron status in STZ-induced type 1 diabetic rats with or without insulin therapy. Body weight, blood glucose, and iron status.

Glucose, insulin, and AGE levels during an OGC before and after RT

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Decreased GLP-1 receptor expression in islets after exposure to high glucose. Decreased GLP-1 receptor expression in islets after exposure to high glucose.

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

1018-NT-β-cell clusters protect mice from STZ-induced diabetes.

Chronic brain insulin infusion reduces liver TG content independent of changes in body weight and food intake. Chronic brain insulin infusion reduces liver.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.

Liver AMPK is activated by oral administration of canagliflozin in mice, but this does not explain changes in RER. A: Phosphorylation of AMPK, ACC, and.

Effect of the acute administration of benzylamine plus vanadate on oral glucose tolerance test in STZ-induced diabetic rats. Effect of the acute administration.

Arterial plasma glucose level and peripheral GIR in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with vehicle.

A: Insulin-stimulated total, oxidative, and nonoxidative glucose disposal in subjects with NGT (open bars), IFG (dotted bars), IGT (striped bar), IFG/IGT.

Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different.

Plasma growth hormone concentrations during a 65-min infusion of acyl ghrelin at 0.3, 0.9, or 1.5 nmol/kg/h, or saline. Plasma growth hormone concentrations.

A: The correlation between the GIR and FGU, each measured during the last 40 min of the euglycemic insulin clamp. A: The correlation between the GIR and.

Measurement of insulin release from islets evoked by glucose, diazoxide, and high K+. Measurement of insulin release from islets evoked by glucose, diazoxide,

Glucose tolerance in WT and TRPM2-KO mice.

Somatostatin released by δ-cells exerts a tonic inhibition on glucagon and insulin secretion but is not required for the glucagonostatic effect of glucose.

Adipose tissue dysfunction induces increased liver HIF-1α expression

Fig. 2 HHKO mice exhibit improved glucose tolerance by increasing plasma incretin levels and insulin secretion. HHKO mice exhibit improved glucose tolerance.

ATL-801 treatment increases insulin sensitivity in KKAY mice.

Arterial and portal plasma glucagon levels and the portal-arterial (P-A) glucagon gradient in the control period (−40 to 0 min) and after administration.

The portal-arterial (P-A) insulin gradient and arterial plasma c-peptide levels in the control period (−40 to 0 min) and after administration of the glycogen.

Hepatic tissue analyses: glycogen concentrations (A), glycogen synthesis via the direct pathway (B), GK mRNA (C), relative (Rel.) GK protein (D), GK activity.

Intracerebroventricular (ICV) insulin infusion increases TG secretion.

Effect of anandamide on blood glucose clearance and insulin sensitivity. Effect of anandamide on blood glucose clearance and insulin sensitivity. A: Intraperitoneal.

Glucose stimulates GLP-1 secretion from the perfused rat intestine by a dose- and absorption-dependent manner. Glucose stimulates GLP-1 secretion from.

The lack of effect of denatonium to stimulate insulin release in the absence of extracellular Ca2+ or in the presence of 10 μmol/l nitrendipine. The lack.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Effect of cold exposure on determinants of glucose tolerance.

Mice fed GP-SPI diet show improved fasting glucose and oral glucose tolerance. Mice fed GP-SPI diet show improved fasting glucose and oral glucose tolerance.

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

Treatment of ob/ob mice with TTR-ASOs improves insulin sensitivity.

Effects of berberine on in vivo metabolism in two animal models of insulin resistance. Effects of berberine on in vivo metabolism in two animal models.

Arterial and hepatic sinusoidal plasma insulin levels in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with.

Loss of Phb2 in β-cells induces development of diabetes over a 3-week period in β-Phb2−/− mice. Loss of Phb2 in β-cells induces development of diabetes.

Pioglitazone lowers glucose overload but only partially improves cardiac function. Pioglitazone lowers glucose overload but only partially improves cardiac.

Effect of cocaine on locomotion.

Chronic rapamycin treatment impairs β-cell mass and insulin clearance in rats. Chronic rapamycin treatment impairs β-cell mass and insulin clearance in.

Pioglitazone administration acutely reduces whole-body energy expenditure in Wistar rats. Pioglitazone administration acutely reduces whole-body energy.

Effects of rhein on FBG (A) and glucose intolerance (B) in db/db mice.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Effect of PPARγ agonist on Aβ phagocytosis in primary microglia.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

A: Pharmacokinetic (plasma insulin concentration) response to administration of an oral insulin formulation (uninterrupted line) and subcutaneous regular.

Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1, 2, or 3 days after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c.

Induction of liver NQO1 activity in juvenile female rats treated for 3 d (10 mg/kg qd SERMs or 0.1 mg/kg qd E2 or vehicle control). Induction of liver.

Plasma concentration of metabolite M1 (left panel), glucose infusion rate (GIR) to maintain euglycemia (middle panel), and blood glucose concentration.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

Plasma metformin concentrations and bioavailability after administration of a single daily dose (study 1). Plasma metformin concentrations and bioavailability.

Presentation transcript:

Pioglitazone administration acutely inhibits insulin secretion and increases insulin clearance in Wistar rats. Pioglitazone administration acutely inhibits insulin secretion and increases insulin clearance in Wistar rats. Two-step HGCs were performed in animals 45 min after pioglitazone (black symbols or bars; 30 mg/kg) or vehicle (control; white symbols or bars) administration by gavage. Glycemia was clamped consecutively at 8.3 mmol/L (first step, from min 30 to 60) and 16.7 mmol/L (second step, from min 90 to 120) as represented by dotted areas, and then an arginine bolus (174 mg/kg) was administered (min 120, after last sampling). Plasma glucose values (A), glucose infusion rate (GIR) (B), plasma insulin (C), and plasma C-peptide concentrations (D) during the procedures. Two-way repeated-measures ANOVA post hoc analyses: *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle-treated group. E: Increment in plasma insulin and C-peptide concentrations 1 min after arginine administration. F: Insulin clearance estimated via C-peptide over insulin/molar ratio for first (30–60 min) and second (90–120 min) steps of the clamps. Unpaired t test: *P < 0.05 vs. vehicle-treated group. Data expressed as means ± SEM, n = 7–8 animals. Inc, increment; Pio, pioglitazone; Ctl, control; Ins, insulin; C-pep, C-peptide; Arg, arginine. Julien Lamontagne et al. Diabetes 2013;62:2122-2129 ©2013 by American Diabetes Association